Curative Biotechnology Announces Good Laboratory
Practice (GLP) Toxicology Studies with Metformin Eye Drop
Formulations for Treatment of Macular Degeneration
National Eye Institute (NEI) to
Collaborate with Curative Biotechnology under Cooperative Research
and Development Agreement (CRADA)
Boca Raton, FL -- May 3, 2022
-- InvestorsHub NewsWire -- Curative Biotechnology, Inc. (OTC:
CUBT) ("Curative Biotech" or the "Company"), a
development-stage biomedical company focused on novel treatments
for rare diseases and conditions, announced today the company has
advanced into its Good Laboratory Practice (GLP) toxicology
study.
The current study is designed to gauge tolerability,
pharmacokinetics and any local or systemic toxicity of reformulated
metformin when administered by topical ocular delivery. The
study will also assess its ocular tissue distribution.
The Good Laboratory Practice (GLP) toxicology study is a
requirement for an FDA Investigational New Drug (IND) filing.
Ocular tolerance includes
observations at dosing, general clinical observations twice daily
(evaluation of behavior/clinical signs with particular attention
paid to the eyes), ophthalmic examinations by a Board-certified
veterinary ophthalmologist according to the modified
Hackett-McDonald scoring scale, and ocular histopathology.
Under a Cooperative Research and
Development Agreement (CRADA), the National Eye Institute (NEI) and
Curative Biotechnology, Inc. will collaborate to evaluate
Curative's proprietary ocular metformin formulation in clinical
studies for the treatment of intermediate and late-stage
Age-Related Macular Degeneration (AMD) disease.
Future Curative Biotechnology Press Releases and
Industry Updates
Interested investors and shareholders
will receive press releases and industry updates by sending an
e-mail to ir@curativebiotech.com.
About Curative Biotechnology, Inc. http://curativebiotech.com
Curative Biotechnology, Inc.
(Curative Biotech) is a development stage biomedical company
focused on novel therapies for rare diseases. The Company is
focused on identifying, acquiring and developing disease modifying
therapeutic drug candidates with a concentration on rare disease
indications. Curative Biotech has ongoing programs in three
different therapeutic areas: infectious disease, neuro oncology and
degenerative eye disease. The Company's pipeline includes IMT504,
CURB906 and Metformin Reformulation. IMT504 is a novel immune
therapy to treat rabies and an adjuvant for vaccines, CURB906 is a
fully humanized CD56 monoclonal antibody carrying a cytotoxic drug
conjugate directly to the tumor cancer site to kill the tumor by
inhibiting tumor growth and migration of the tumor. Metformin
Reformulation is targeting the treatment of intermediate and
late-stage Age-Related Macular Degeneration (AMD) disease.
Forward-Looking
Statements
This press release contains
"forward-looking statements" within the meaning of Section 27A of
the Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934. CUBT is not yet generating
revenues. Although forward-looking statements in this release
reflect the good faith judgment of management,
forward-looking statements are inherently subjected to known,
unknown risks and uncertainties that may cause actual results
to be materially different from those discussed in these
forward-looking statements, including but not limited our
ability to generate sufficient market acceptance for our products
and services, our ability to generate sufficient operating
cash flow, and general economic conditions. Readers are urged
to carefully review and consider the various disclosures made by us
in our reports filed with OTC Markets from time to time which
attempt to advise interested parties of the risks and factors that
may affect our business, financial condition, results of
operation and cash flows. If one or more of these risks or
uncertainties materialize, or if the underlying assumptions prove
incorrect, our actual results may vary materially from those
expected or projected. Readers are urged not to place undue
reliance on these forward-looking statements, which speak only as
of the date of this release. We assume no obligation to update any
forward-looking statements in order to reflect any event or
circumstance that may arise after the date of this release.
Contact:
Steve Chizzik
Investor Relations
Curative Biotech (CUBT)
201-454-5845
ir@curativebiotech.com
